Sort
30,917 grants matching “tumor microenvironment”
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
$430,969William J Aronson · University Of California Los Angeles · R01 · FY2021 · CA
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
$430,969William J Aronson · University Of California Los Angeles · R01 · FY2020 · CA
NextGen - CHOP
$430,950John M Maris · Children'S Hosp Of Philadelphia · OT2 · FY2022 · CA
Pathology Core
$430,936Geoffrey I Shapiro · Dana-Farber Cancer Inst · P01 · FY2024 · CA
Novel therapy targeting refractory colon cancer
$430,907Ping-Ying Pan · Methodist Hospital Research Institute · R01 · FY2017 · CA
Project 3: A novel telomere-targeted agent for neoadjuvant therapy of early-stage HCC
$430,751Adam Yopp · Ut Southwestern Medical Center · P50 · FY2025 · CA
3' RNA modification enzymes regulate tumor angiogenesis in non-small lung cancer
$430,684Seyedtaghi Takyar · Yale University · R21 · FY2024 · CA
Personalization and Failure Testing of Dual Switch Gene Drives in Lung Cancer
$430,636Justin Pritchard · Pennsylvania State University, The · U01 · FY2024 · CA
Abnormal Stem Cell Trafficking in IM
$430,631Ronald Hoffman · Icahn School Of Medicine At Mount Sinai · P01 · FY2012 · CA
Pregnancy, Obesogenic Environments, and Basal-like Breast Cancer
$430,559Melissa A. Troester · Univ Of North Carolina Chapel Hill · U01 · FY2011 · ES
Phenotype Interactions and Dynamics in SCLC Tumors
$430,496Alissa M Weaver · Vanderbilt University · U54 · FY2021 · CA
Exploring enzyme-instructed self-assembly (EISA) for targeting osteoblastic metastasis of prostate cancer
$430,496Bing Xu · Brandeis University · R21 · FY2020 · CA
Tumor cell -TAM Paracrine Signaling in Breast Cancer
$430,489Elizabeth S. Yeh · Indiana University Indianapolis · R01 · FY2024 · CA
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer
$430,481Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell Carcinoma
$430,452Jeffrey C Rathmell · Vanderbilt University Medical Center · R01 · FY2022 · CA
What fuels CAR T-cell serial killing
$430,406Roderick O'Connor · University Of Pennsylvania · R01 · FY2023 · CA
Immune cell control of ovarian cancer
$430,385Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Human Organoid Models for Pediatric High-Grade Gliomas
$430,375Renee D Read · Emory University · R21 · FY2023 · NS
GLIOMA INTERACTION WITH THE NEUROGENIC NICHE THROUGH EXTRACELLULAR VESICLES
$430,375Hugo Guerrero-Cazares · Mayo Clinic Jacksonville · R21 · FY2024 · NS
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma
$430,368Yolonda L Colson · Brigham And Women'S Hospital · R01 · FY2016 · EB
Preclinical development of WP1066, an effective inhibitor of STAT3 activation for
$430,262Raymond J Budde · Houston Pharmaceuticals, Inc. · R44 · FY2010 · AI
The integrated stress response and the microenvironment in melanoma progression
$430,251Constantinos Koumenis · University Of Pennsylvania · R01 · FY2022 · CA
Brain Tumor Immunotherapy
$430,226Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
$430,212Edgar G. Engleman · Stanford University · P01 · FY2025 · CA
Project 2
$430,137Rory Smoot · Mayo Clinic Rochester · P50 · FY2024 · CA